Douglas B. Evans mostly deals with Surgery, Pancreatic cancer, Pancreatic disease, Pancreas and Cancer research. Douglas B. Evans interconnects Neoadjuvant therapy, Growth factor and Oncology in the investigation of issues within Pancreatic cancer. His research on Pancreatic disease also deals with topics like
His Pancreas research incorporates themes from Growth factor receptor, Radiology and Superior mesenteric vein. His Cancer research research integrates issues from Carcinogenesis, Regulation of gene expression, Transcription factor and Pancreatic tumor. His biological study spans a wide range of topics, including Gastroenterology and Endocrinology.
His primary areas of investigation include Pancreatic cancer, Internal medicine, Surgery, Oncology and Adenocarcinoma. His Pancreatic cancer study incorporates themes from Neoadjuvant therapy, Cancer research, Chemotherapy, Radiation therapy and Pancreatic disease. As a part of the same scientific study, Douglas B. Evans usually deals with the Internal medicine, concentrating on Pathology and frequently concerns with Metastasis.
His studies in Surgery integrate themes in fields like Parathyroidectomy and Radiology. The Oncology study combines topics in areas such as CA19-9, Borderline resectable and Disease. His study in Adenocarcinoma is interdisciplinary in nature, drawing from both Surgical oncology, General surgery and Pancreas.
The scientist’s investigation covers issues in Pancreatic cancer, Internal medicine, Oncology, Neoadjuvant therapy and Surgery. His studies deal with areas such as Cancer research, Pancreatectomy, Borderline resectable, Disease and Adjuvant therapy as well as Pancreatic cancer. His study in the fields of Cancer, Chemotherapy and Gemcitabine under the domain of Internal medicine overlaps with other disciplines such as In patient.
Pancreas is closely connected to Neuroendocrine tumors in his research, which is encompassed under the umbrella topic of Oncology. His research integrates issues of Clinical trial and Multimodality Therapy, Chemoradiotherapy, Radiation therapy, Overall survival in his study of Neoadjuvant therapy. He has researched Surgery in several fields, including Parathyroidectomy, Adrenocortical carcinoma and Thyroidectomy.
Douglas B. Evans mainly focuses on Surgery, Pancreatic cancer, Internal medicine, Neoadjuvant therapy and Retrospective cohort study. His Surgery research is multidisciplinary, incorporating elements of Parathyroidectomy, Adrenocortical carcinoma and Urology. His Pancreatic cancer study integrates concerns from other disciplines, such as Stromal cell, Cancer research, Combined Modality Therapy, Radiology and Adjuvant therapy.
Douglas B. Evans interconnects Pancreaticoduodenectomy, Pancreas and Endocrine system in the investigation of issues within Radiology. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Oncology. His biological study spans a wide range of topics, including Borderline resectable and Radiation therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao;Manal Hassan;Alexandria T. Phan;Cecile Dagohoy.
Journal of Clinical Oncology (2008)
Management of thyroid nodules detected at US: Society of radiologists in ultrasound consensus conference statement
Mary C. Frates;Carol B. Benson;J. William Charboneau;Edmund S. Cibas.
Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T. Kloos;Charis Eng;Douglas B. Evans;Gary L. Francis.
Revised American thyroid association guidelines for the management of medullary thyroid carcinoma
Samuel A Wells;Sylvia L Asa;Henning Dralle;Rossella Elisei.
Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
Rosa Frances Hwang;Todd Moore;Thiruvengadam Arumugam;Vijaya Ramachandran.
Cancer Research (2008)
The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells
Weixin Wang;James L. Abbruzzese;Douglas B. Evans;Lillie Larry.
Clinical Cancer Research (1999)
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong.
Annals of Surgical Oncology (2006)
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun.
Journal of The American College of Surgeons (2008)
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Douglas B. Evans;Tyvin A. Rich;David R. Byrd;Karen R. Cleary.
Archives of Surgery (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: